ChemoMetec A/S (LON: 0DZ0)

Market Cap	1.00B
Revenue (ttm)	46.37M
Net Income (ttm)	15.49M
Shares Out	n/a
EPS (ttm)	0.89
PE Ratio	64.86
Forward PE	n/a
Dividend	0.45 (0.09%)
Ex-Dividend Date	Oct 11, 2024

Volume	624
Average Volume	610
Open	524.50
Previous Close	518.00
Day's Range	516.50 - 525.00
52-Week Range	31.36 - 61.56
Beta	n/a
RSI	54.81
Earnings Date	Feb 5, 2025

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 174
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DZ0

Financial Performance

In 2024, ChemoMetec's revenue was 407.87 million, a decrease of -8.22% compared to the previous year's 444.40 million. Earnings were 136.28 million, a decrease of -23.72%.

Financial numbers in DKK